One-in-a-million people are living with EHE worldwide.

Our mission is to find treatments and a cure for epithelioid hemangioendothelioma (EHE) by advancing research and driving collaboration among patients, researchers, and clinicians.

We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.

Patient-Powered EHE Research

EHE Biobank

Patients are the key to finding new treatments for EHE! Researchers need tumor tissue and fluid from EHE patients to understand disease progression and speed the development of new drugs and therapies.

Patient-Powered EHE Research

EHE Global Patient Registry

The EHE Global Patient Registry empowers people with Epithelioid Hemangioendothelioma (EHE) to join together to improve our understanding of this ultra-rare sarcoma. We need every EHE patient to join this critical tool used to support researchers searching for treatments and a cure for EHE.

Latest EHE News, Events and Research

Giving Tuesday 2019 WrapUp

By EHE Foundation | December 27, 2019

We are THRILLED to announce that we surpassed our #GivingTuesday donations from last year! We are excited to share the total on Tuesday, December 10th. We are beyond GRATEFUL! THANK YOU to our many compassionate supporters for giving hope to those suffering from EHE. It is inspiring to know that our grassroots fundraising will continue to advance […]

EHE Research Update Teleconference – Nov 2nd

By EHE Foundation | October 29, 2019

Please join us for our annual “EHE Research Update” teleconference on Saturday, November 2, 2019 from 4:00 pm to 5:30 pm Eastern Standard Time (US). Jane Gutkovich, The EHE Foundation’s Director of Research, will be going over these main topics: What is EHE? Or rather EHEs? Why we all are so different? What have we […]

International Sarcoma Kindred Study (ISKS)

By EHE Foundation | October 11, 2019

What is ISKS? ISKS is . afree to participate global genetic, biological, epidemiological, clinical resource developed to understand the genetic basis of sarcoma in a population. ISKS has created a world first, one of a kind, database that is accessed by doctors, researchers and scientists across the globe. ISKS was developed by Australian EHE Medical […]

Stay up to Date on EHE by Reading The Pledge: Edition 18, Q3 – July-Sept, 2019

By EHE Foundation | October 5, 2019

Click here to read the Pledge: Edition 18, Q3 – July-Sept, 2019

EHE Foundation at ASCO 2019!

By EHE Foundation | October 1, 2019

EHE Foundation joined over 30,000 cancer experts from around the world in Chicago, IL in early June to learn of the latest clinical cancer research impacting patient care. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient. EHE Foundation board members and staff participated in the patient advocate track […]

Stay up to Date on EHE by Reading The Pledge: Edition 17, Q2 – April-June, 2019

By EHE Foundation | September 13, 2019

Click here to read the Pledge: Edition 17, Q2 – April-June, 2019

The Pledge: Edition 43, Q4 – October-December, 2025

By EHE Foundation | February 15, 2026

Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content, including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.

Understanding Quality of Life for People Living With EHE

By Kristianne Oristian, PhD | February 10, 2026

The European Organisation of Research and Treatment of Cancer (EORTC) is conducting research to better understand health-related quality of life (HRQoL) concerns among people living with rare cancers. Recently, researchers analyzed results from a group of 31 people with EHE from 11 different countries who participated in the study. The findings showed that pain–and the […]

Exploring Eribulin as a Potential Treatment Option for EHE

By Kristianne Oristian, PhD | February 10, 2026

Prior research has shown that a class of medications called microtubule inhibitors may be effective at controlling the growth of EHE tumors. Recently, researchers conducted a phase 2 study to test whether the microtubule inhibitor eribulin is a safe and effective way to treat patients whose tumors continued to grow after prior treatment. Six (6) […]